How are BPC-157 and TB-500 sold, mixed and measured in units?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Filled in from the blend in the Milligram app's catalogue (10 mg + 10 mg). Change them to match your vial.
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds BPC-157 + TB-500 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
BPC-157 and TB-500 are sold both as one blend vial and as separate vials, FDA records,1 and a search of the US DailyMed label database found no label for either;23 of people logging the blend, 38% set up a 1 mg dose.16
The guide's example
1,000 mcg of BPC-157 + TB-500 from a 20 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 10 mg47% set up16 | 10 mg/mL: 500 mcg is 5 units, 1,000 mcg is 10 units, 2,000 mcg is 20 units | 5 mg/mL: 500 mcg is 10 units, 1,000 mcg is 20 units, 2,000 mcg is 40 units | 3.333 mg/mL: 500 mcg is 15 units, 1,000 mcg is 30 units, 2,000 mcg is 60 units |
| 20 mg48% set up16 | 20 mg/mL: 500 mcg is 2.5 units, 1,000 mcg is 5 units, 2,000 mcg is 10 units | 10 mg/mL: 500 mcg is 5 units, 1,000 mcg is 10 units, 2,000 mcg is 20 units | 6.667 mg/mL: 500 mcg is 7.5 units, 1,000 mcg is 15 units, 2,000 mcg is 30 units |
Blend or two vials
Of people logging the blend, 48% set up a 20 mg vial and 47% a 10 mg vial.16 FDA records one website selling a BPC-157 and TB-500 10 mg injectable, and a case report of a product sold as 5 mg of each and labelled for research purposes only.1
Each peptide is also sold on its own: FDA records a website selling BPC-157 5 mg and 10 mg products,1 and several websites offering TB-500 as 2, 3, 5, 10 and 15 mg powders for research use only.4 No label or trial found compares two separately mixed vials with a blend.
Water, syringe units and a worked mix
No label gives the water volume for a blend vial, and the written reconstitution instructions FDA found for TB-500 came from one website selling it.4 Hospira's bacteriostatic water contains benzyl alcohol in a multiple-dose container, while Medefil's sterile water has no bacteriostat and is single-dose.56 Hospira's label says the volume used to dissolve a drug is dependent on the vehicle concentration, dose and route of administration as recommended by the drug's manufacturer.5 Of people logging the blend, 29% set up 20 mg with 2 mL of water.16 The Humulin R label gives U-100 as 100 units per mL;7 the units here are marks on a U-100 syringe, not IU of the drug. The table, worked mix and calculator take the vial's figure as both peptides together; FDA's case report describes a blend sold as 5 mg of each (5mg/5mg).1
1,000 mcg of BPC-157 + TB-500 from a 20 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
29% set up 20 mg + 2 mL16
Dose, schedule and route in labels, trials and logs
No label gives a dose for BPC-157, TB-500 or the blend.23 The nearest reports of the two together are the Lee and Padgett knee chart review, where some patients had BPC 157 with thymosin-beta-4 (TB4), often conflated with TB-500,89 and the Froum dental case report, where both were given with other agents.10
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Lee and Padgett, 2021, knee chart review8 | BPC-157 2 to 4 mg into the joint, once or twice1; 4 of the 16 patients reached also had thymosin-beta-4 (TB4), dose not stated | 17 | Follow-up varied |
| NCT07487363, TB-500 alone, adults with stable ASCVD, recruiting11 | Three sequential dose cohorts randomised 3:1 to TB-500 or placebo; dose levels not public | 80 (estimated) | 8 weeks of dosing, then 4 weeks of safety follow-up |
Of people logging the blend, 38% set up 1 mg, 14% 2 mg and 9% 0.5 mg.16 By unit, 58% logged the dose in mg, 31% in mcg and 11% in IU.16
FDA found no study that gave BPC-157 to humans by the subcutaneous route it was reviewing.1 ClinicalTrials.gov lists two BPC-157 trials with once-daily subcutaneous dosing and no stated dose: NCT07803250, 30 participants (estimated), 90 days after rotator cuff repair, not yet recruiting,12 and NCT07437547, placebo-controlled, 120 participants (estimated), 14 days after a hamstring strain.13 FDA records one adverse-event report of a 40-year-old woman who used a BPC-157 and TB-500 product under the skin twice daily; because it held two peptides, FDA says the role of BPC-157 cannot be assessed.1 None of the trials found named a subcutaneous injection site. Of people logging the blend, 96% logged it under the skin.16
Storage
FDA reports that lyophilized (freeze-dried) BPC-157 free base is stable at room temperature for 3 weeks, and that it is recommended to be stored desiccated below -18°C because moisture greatly decreases the long-term stability of lyophilized peptides.1 Once reconstituted, BPC-157 free base in solution is stable for 2 to 3 weeks at 4°C and 3 to 4 months at -20°C, FDA reports.1 For TB-500, FDA reports the free base is stable below -20°C when sealed, away from moisture and light, under nitrogen, and the acetate below -15°C, protected from light in a tightly closed container.4 FDA gives no stability figures for the two peptides mixed in one vial. Hospira's water label says reconstituted solutions are not to be stored unless the drug's own manufacturer directs otherwise.5
Frequently asked questions
Is there a human trial of TB-500 alone?
A ClinicalTrials.gov search for TB-500 returned one trial, NCT07487363, which is recruiting and does not publish its dose levels.1411 FDA found no clinical studies or human exposure data for TB-500 by any route.4 A case report of three dental patients by Froum and colleagues gave TB-500 with BPC-157 and other agents.10
Does a vial hold what its label says?
- BPC-157 + TB-500The compound page.
- CalculatorThe mixing calculator for the blend.
- Related compoundsPeptides in the same class.
- MixingGeneral steps for a powder vial.
- How to mix KLOWThe four-peptide blend that contains both.
- BPC-157 dosageBPC-157 on its own.
- Glutathione dosageAnother injected powder.
- Wolverine stack vs Glow protocolBPC-157 and TB-500, with or without GHK-Cu.
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: BPC-157 (free base and acetate). 2026. fda.gov
- US National Library of Medicine DailyMed. DailyMed label search for BPC-157 (returned zero labels). 2026. dailymed.nlm.nih.gov
- US National Library of Medicine DailyMed. DailyMed label search for TB-500 (returned zero labels). 2026. dailymed.nlm.nih.gov
- US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: TB-500 (free base and acetate). 2026. fda.gov
- Hospira via DailyMed. Bacteriostatic Water for Injection, USP (Hospira) prescribing information. 2026. dailymed.nlm.nih.gov
- Medefil via DailyMed. Sterile Water for Injection, USP (Medefil) prescribing information. 2026. dailymed.nlm.nih.gov
- Eli Lilly via DailyMed. Humulin R (insulin human) injection prescribing information (U-100 concentration). 2026. dailymed.nlm.nih.gov
- Altern Ther Health Med (PubMed abstract). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. 2021. pubmed.ncbi.nlm.nih.gov
- J Am Acad Orthop Surg (PubMed abstract). Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. 2026. pubmed.ncbi.nlm.nih.gov
- Frontiers in Oral Health (Europe PMC full text). Case Report: Regenerative peptides for Inferior alveolar nerve injury (full text). 2026. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT07487363 TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT07803250 Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. 2026. clinicaltrials.gov
- ClinicalTrials.gov. NCT07437547 BPC 157 for Acute Hamstring Muscle Strain Repair. 2026. clinicaltrials.gov
- ClinicalTrials.gov. ClinicalTrials.gov registry search by intervention: TB-500. 2026. clinicaltrials.gov
- Therapeutic Goods Administration (Australia). TGA testing finds unapproved peptides do not contain what their labels claim. 2026. tga.gov.au
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted